Waystar (WAY) Q1 2026 earnings review
Subscription Mix Shift Powers Growth as Transitory Tailwinds Fade
Waystar delivered a strong start to 2026, with top-line revenue accelerating 22% YoY to $313.9M, largely driven by the full integration of the Iodine Software acquisition. The company continues to demonstrate excellent profitability, expanding its Adjusted EBITDA margin to 43.1%. However, beneath the headline beat, organic metrics are normalizing: Net Revenue Retention (NRR) decelerated to 111% as the windfall from a competitor's 2024 cyber event fades, and volume-based revenue growth slowed to just 7%. Full-year FY26 guidance projects $1.284B in revenue at the midpoint, confirming a stable, highly profitable trajectory despite shifting growth drivers.
🐂 Bull Case
Subscription revenue surged 38% YoY to $172.2M, fueled by the Iodine integration and organic platform adoption. This highly recurring revenue stream now makes up nearly 55% of total sales, improving visibility and margin resilience.
Adjusted EBITDA margin expanded sequentially and YoY to 43.1%. Management is successfully extracting the promised >$15M in Iodine cost synergies while maintaining aggressive investments in AI.
🐻 Bear Case
Volume-based revenue grew only 7% YoY, a sharp deceleration from 11-14% growth in early 2025. This signals that the elevated patient utilization tailwinds experienced last year are reverting to the historical 1-2% baseline.
Net Revenue Retention has steadily decelerated from its 115% peak to 111%. While management flagged this as a return to the historical 108-110% average post-Change Healthcare disruption, it mechanically limits organic growth upside.
⚖️ Verdict: 🟢
Bullish. While organic retention and volume growth are decelerating toward historical averages, Waystar's pivot toward high-margin, AI-driven subscription software (bolstered by Iodine) is working perfectly. A 43% EBITDA margin paired with 22% top-line growth is a top-tier software profile.
Key Themes
Subscription Revenue Overtakes Volume
The structural shift in Waystar's business model is accelerating. Subscription revenue grew 38% YoY to $172.2M, dwarfing the 7% growth in volume-based revenue. This is a direct result of integrating Iodine's 100% subscription model and a deliberate go-to-market focus on recurring, SaaS-based platform commitments over transactional fees.
Launch of AI-Powered Recoupment
Waystar officially launched its new AI-powered recoupment solution this quarter, expanding the AltitudeAI suite. With previous iterations (like Auth Accelerate) generating 85% auto-approval rates, this new module acts as a direct monetization lever, allowing Waystar to price based on the hard ROI of recovered provider revenue.
Enterprise Client Base Expanding
The company added significant scale at the enterprise level, with clients contributing over $100,000 in LTM revenue reaching 1,433. This represents a 15% YoY increase (up from 1,244 in 25Q1), confirming that large health systems are standardizing on Waystar's consolidated platform rather than point solutions.
Deceleration in Volume-Based Revenue
Volume-based revenue grew just 7% YoY to $139.5M, a notable deceleration from the low double-digit growth seen throughout 2025. This confirms prior management warnings that elevated patient utilization trends—which boosted patient payment processing—are reverting to historical norms. Any macroeconomic pressure on elective procedures or consumer payment capacity will disproportionately impact this segment.
NRR Normalization Path
Net Revenue Retention fell to 111%, down sequentially from 112% and from a peak of 115% in 25Q2. The mechanical tailwind from rapidly onboarding clients during a competitor's 2024 cyber event has fully lapped. The question remains whether NRR will stabilize here or dip below the historical 108-110% range.
Margin Expansion Through Synergies
Adjusted EBITDA margins hit 43.1%, up from 42.0% a year ago. This implies the company is successfully executing on its target to realize over 90% of the $15M in Iodine cost synergies in 2026. Management's discipline in balancing high organic AI investment with structural cost removal is playing out in the financials.
Other KPIs
A strong conversion profile continues. UFCF grew 15% YoY from $78.8M in 25Q1, representing an outstanding 67% conversion of Adjusted EBITDA. Operating cash flow checked in at $84.9M alongside modest capital expenditures of $15.3M.
Leverage remains healthy. Despite absorbing the $1.25B Iodine acquisition in late 2025, Waystar has already deleveraged to 2.7x (down from a pro-forma 3.5x at the time of the deal), supported by strong EBITDA growth and robust cash generation. Net debt sits at $1.32B.
Guidance
Stable. The midpoint of $1.284B implies approximately 17% YoY growth over FY25's $1.099B. This incorporates a full year of Iodine revenue alongside an assumed ~10% organic growth rate for the core business.
Stable. The midpoint ($535M) implies an annual Adjusted EBITDA margin of 41.7%. This is slightly below the 43.1% achieved in Q1, indicating management plans to aggressively reinvest operational leverage into product development and GTM later in the year.
Accelerating. Implies a 24% YoY growth at the midpoint compared to FY25's $262.9M, demonstrating excellent flow-through to the bottom line as debt is paid down and integration costs subside.
Key Questions
Volume-Based Revenue Slowdown
Volume-based revenue decelerated to 7% YoY growth this quarter. How much of this is driven by normalizing patient utilization versus a shift in market share or pricing dynamics?
NRR Stabilization
With NRR stepping down to 111%, have we fully lapped the tailwinds from the 2024 competitor disruption, and is 108-110% still the targeted structural floor?
AI Recoupment Adoption
Can you provide early color on the pipeline for the newly launched AI-powered recoupment solution? How is it being priced (SaaS vs contingency), and how does it alter the TAM?
Iodine Cross-Sell Progress
Six months post-acquisition, what percentage of the historical Waystar base has adopted an Iodine mid-cycle module, and vice versa?